News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
394,805 Results
Type
Article (32134)
Company Profile (145)
Press Release (362526)
Section
Business (103479)
Career Advice (586)
Deals (14989)
Drug Delivery (55)
Drug Development (63403)
Employer Resources (54)
FDA (10746)
Job Trends (8848)
News (192304)
Policy (16741)
Tag
Academia (2093)
Alliances (28699)
Alzheimer's disease (870)
Antibody-drug conjugate (ADC) (96)
Approvals (10715)
Artificial intelligence (106)
Bankruptcy (125)
Best Places to Work (7554)
Biotechnology (114)
Breast cancer (216)
Cancer (1581)
Cardiovascular disease (81)
Career advice (478)
CAR-T (107)
Cell therapy (261)
Clinical research (51421)
Collaboration (385)
Compensation (109)
COVID-19 (1548)
C-suite (79)
Data (1200)
Diabetes (94)
Diagnostics (4324)
Earnings (33927)
Events (63760)
Executive appointments (290)
FDA (11291)
Funding (310)
Gene therapy (112)
GLP-1 (289)
Government (2716)
Healthcare (13286)
Infectious disease (1608)
Inflammatory bowel disease (71)
Interviews (77)
IPO (7230)
Job creations (1617)
Job search strategy (449)
Layoffs (233)
Legal (2646)
Liver cancer (72)
Lung cancer (240)
Lymphoma (103)
Manufacturing (103)
Medical device (6933)
Medtech (6936)
Mergers & acquisitions (7883)
Metabolic disorders (243)
Neuroscience (1100)
NextGen: Class of 2025 (4170)
Non-profit (3536)
Northern California (1244)
Obesity (124)
Opinion (86)
People (32900)
Phase I (16517)
Phase II (22689)
Phase III (16614)
Pipeline (432)
Postmarket research (1960)
Preclinical (6554)
Prostate cancer (72)
Radiopharmaceuticals (231)
Rare diseases (184)
Real estate (3518)
Regulatory (12470)
Research institute (1968)
Resumes & cover letters (84)
Southern California (976)
Startups (2040)
United States (10655)
Vaccines (402)
Date
Today (77)
Last 7 days (574)
Last 30 days (1357)
Last 365 days (22695)
2025 (856)
2024 (22792)
2023 (25752)
2022 (33483)
2021 (35402)
2020 (32890)
2019 (28477)
2018 (21414)
2017 (19611)
2016 (18774)
2015 (21750)
2014 (16432)
2013 (13154)
2012 (13966)
2011 (14531)
2010 (13233)
Location
Africa (324)
Arizona (89)
Asia (23569)
Australia (3819)
California (2628)
Canada (885)
China (258)
Colorado (124)
Connecticut (133)
Europe (48320)
Florida (361)
Georgia (100)
Illinois (285)
Indiana (134)
Maryland (704)
Massachusetts (2107)
Michigan (83)
Minnesota (176)
New Jersey (791)
New York (796)
North Carolina (445)
Northern California (1244)
Ohio (90)
Pennsylvania (622)
South America (444)
Southern California (976)
Texas (441)
Washington State (299)
394,805 Results for "md anderson cancer center".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
OneOncology Partners with Anderson Area Cancer Center
Anderson Area Cancer Center and OneOncology announced a finalized partnership to enhance the delivery of cancer services in and around Anderson, South Carolina.
June 24, 2024
·
2 min read
Business
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and The University of Texas MD Anderson Cancer Center today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
April 16, 2024
·
8 min read
Press Releases
AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease
December 10, 2024
·
4 min read
Business
Sibylla Biotech and MD Anderson Announce Strategic Collaboration to Discover and Develop Small-Molecule Protein Degraders
Sibylla Biotech and The University of Texas MD Anderson Cancer Center announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as Folding Interfering Degraders, which disrupt the proper folding of target proteins and lead to their degradation.
June 12, 2024
·
4 min read
Business
Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center
Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, leading expert in cancer immunotherapy and cancer center chief executive, has been named the executive director of UNC Lineberger Comprehensive Cancer Center, and UNC system chief of oncology services, effective October 1st, announced UNC School of Medicine Dean Wesley Burks, MD.
June 19, 2024
·
5 min read
Press Releases
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
January 8, 2025
·
4 min read
Business
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a multi-year strategic development collaboration to expand the evaluation of REZLIDHIA ® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers.
December 8, 2023
·
11 min read
Policy
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
Replay and The University of Texas MD Anderson Cancer Center, announced that the Food & Drug Administration has issued a ‘safe to proceed’ for the Investigational New Drug application for PRAME TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer cell therapy for relapsed/refractory myeloid malignancies.
April 30, 2024
·
5 min read
Lone Star Bio
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that investigators at the University of Texas MD Anderson Cancer Center’s Leukemia department presented clinical data on seclidemstat in patients with MDS and CMML at the 2024 European Hematology Association (EHA) Hybrid Congress.
June 17, 2024
·
7 min read
Press Releases
J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment ‘JIN-001' - Enhancing Radiation and Chemotherapy Efficacy
November 25, 2024
·
2 min read
1 of 39,481
Next
